Regeneron presents Otarmeni long-term safety and efficacy data at medical conferences

Regeneron Pharmaceuticals/Otarmeni (DB-OTO)

Regeneron presented extended follow-up data from the CHORD trial at scientific conferences, demonstrating sustained hearing improvement and a favorable safety profile in Otarmeni-treated patients beyond the initial 24-week assessment period.